Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 240

1.

Ibrutinib (PCI-32765), the first BTK (Bruton's tyrosine kinase) inhibitor in clinical trials.

Brown JR.

Curr Hematol Malig Rep. 2013 Mar;8(1):1-6. doi: 10.1007/s11899-012-0147-9. Review.

2.

Ibrutinib treatment of CLL: the cancer fights back.

Young RM, Staudt LM.

Cancer Cell. 2014 Jul 14;26(1):11-3. doi: 10.1016/j.ccr.2014.06.023.

3.

Ibrutinib: a first in class covalent inhibitor of Bruton's tyrosine kinase.

Davids MS, Brown JR.

Future Oncol. 2014 May;10(6):957-67. doi: 10.2217/fon.14.51. Review.

4.

Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, Grant B, Sharman JP, Coleman M, Wierda WG, Jones JA, Zhao W, Heerema NA, Johnson AJ, Sukbuntherng J, Chang BY, Clow F, Hedrick E, Buggy JJ, James DF, O'Brien S.

N Engl J Med. 2013 Jul 4;369(1):32-42. doi: 10.1056/NEJMoa1215637. Epub 2013 Jun 19. Erratum in: N Engl J Med. 2014 Feb 20;370(8):786.

5.

Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib.

Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC.

N Engl J Med. 2014 Jun 12;370(24):2286-94. doi: 10.1056/NEJMoa1400029. Epub 2014 May 28.

6.

Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton's tyrosine kinase inhibition.

Dias AL, Jain D.

Cardiovasc Hematol Agents Med Chem. 2013 Dec;11(4):265-71. Review.

7.

The emerging role of ibrutinib in the treatment of chronic lymphocytic leukemia.

Molica S.

Expert Rev Hematol. 2013 Oct;6(5):543-6. doi: 10.1586/17474086.2013.831324. Epub 2013 Oct 2.

PMID:
24083545
8.

Bruton's tyrosine kinase (BTK) inhibitors in clinical trials.

Burger JA.

Curr Hematol Malig Rep. 2014 Mar;9(1):44-9. doi: 10.1007/s11899-013-0188-8. Review.

PMID:
24357428
9.

Ibrutinib (PCI-32765) in chronic lymphocytic leukemia.

Jain N, O'Brien S.

Hematol Oncol Clin North Am. 2013 Aug;27(4):851-60, x. doi: 10.1016/j.hoc.2013.01.006. Review.

10.

The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia.

Wiestner A.

Haematologica. 2015 Dec;100(12):1495-507. doi: 10.3324/haematol.2014.119123. Review.

11.

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL).

Woyach JA, Bojnik E, Ruppert AS, Stefanovski MR, Goettl VM, Smucker KA, Smith LL, Dubovsky JA, Towns WH, MacMurray J, Harrington BK, Davis ME, Gobessi S, Laurenti L, Chang BY, Buggy JJ, Efremov DG, Byrd JC, Johnson AJ.

Blood. 2014 Feb 20;123(8):1207-13. doi: 10.1182/blood-2013-07-515361. Epub 2013 Dec 5.

12.

Development of the Bruton's tyrosine kinase inhibitor ibrutinib for B cell malignancies.

Gayko U, Fung M, Clow F, Sun S, Faust E, Price S, James D, Doyle M, Bari S, Zhuang SH.

Ann N Y Acad Sci. 2015 Nov;1358:82-94. doi: 10.1111/nyas.12878. Epub 2015 Sep 8. Review.

PMID:
26348626
13.

[Ibrutinib: A new drug of B-cell malignancies].

Thieblemont C.

Bull Cancer. 2015 Jun;102(6 Suppl 1):S85-90. doi: 10.1016/S0007-4551(15)31222-4. Review. French.

PMID:
26118882
14.

Ibrutinib: a review of its use in patients with mantle cell lymphoma or chronic lymphocytic leukaemia.

Kim ES, Dhillon S.

Drugs. 2015 May;75(7):769-76. doi: 10.1007/s40265-015-0380-3. Review.

PMID:
25802231
15.

Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia.

Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA.

JAMA Oncol. 2015 Apr;1(1):80-7. doi: 10.1001/jamaoncol.2014.218.

16.

Ibrutinib in B lymphoid malignancies.

Smith MR.

Expert Opin Pharmacother. 2015;16(12):1879-87. doi: 10.1517/14656566.2015.1067302. Epub 2015 Jul 13. Review.

PMID:
26165513
17.

A review of a novel, Bruton's tyrosine kinase inhibitor, ibrutinib.

Lee CS, Rattu MA, Kim SS.

J Oncol Pharm Pract. 2016 Feb;22(1):92-104. doi: 10.1177/1078155214561281. Epub 2014 Nov 25. Review.

PMID:
25425007
18.

[Ibrutinib in the treatment of chronic lymphocytic leukemia and other B-cell malignancies].

Wang M, Xu W, Li JY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2014 Feb;22(1):245-9. doi: 10.7534/j.issn.1009-2137.2014.01.049. Review. Chinese.

PMID:
24598688
19.

Ibrutinib: a novel Bruton's tyrosine kinase inhibitor with outstanding responses in patients with chronic lymphocytic leukemia.

Barrientos J, Rai K.

Leuk Lymphoma. 2013 Aug;54(8):1817-20. doi: 10.3109/10428194.2013.796049. Review.

PMID:
23617325
20.

Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies.

Wang Y, Zhang LL, Champlin RE, Wang ML.

Clin Pharmacol Ther. 2015 May;97(5):455-68. doi: 10.1002/cpt.85. Epub 2015 Apr 3. Review.

PMID:
25669675

Supplemental Content

Support Center